• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

43.75 -0.32 (-0.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Synovus Financial, Gilead Sciences And More On CNBC's 'Final Trades'
July 09, 2025
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD. 
Via Benzinga
Beyond The Numbers: 8 Analysts Discuss Kymera Therapeutics Stock
June 26, 2025
 
Via Benzinga
Tesla To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Thursday
June 26, 2025
 
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
June 25, 2025
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. 
Via Stocktwits
What 6 Analyst Ratings Have To Say About Kymera Therapeutics
June 03, 2025
 
Via Benzinga
What's Next: Kymera Therapeutics's Earnings Preview
May 08, 2025
 
Via Benzinga
Demystifying Kymera Therapeutics: Insights From 6 Analyst Reviews
February 28, 2025
 
Via Benzinga
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
June 25, 2025
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
June 25, 2025
From Gilead Sciences, Inc.
Via Business Wire
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
June 12, 2025
Three relatively unknown biopharma firms receive near-unanimous approval from analysts for their promising drug candidates in development. 
Via MarketBeat
Applied Digital And Riot Platforms Are Among Top 10 Mid-Cap Gainers Last Week (Jun 2-Jun 6): Are The Others In Your Portfolio?
June 08, 2025
 
Via Benzinga
Earnings Scheduled For February 27, 2025
February 27, 2025
 
Via Benzinga
The Latest Analyst Ratings For Kymera Therapeutics
November 01, 2024
 
Via Benzinga
Signet Posts Upbeat Earnings, Joins Ferguson Enterprises, Dollar General And Other Big Stocks Moving Higher On Tuesday
June 03, 2025
 
Via Benzinga
Disney To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
June 03, 2025
 
Via Benzinga
Kymera Therapeutics Soars After Multiple Analyst Upgrades; Retail Sentiment Turns Extremely Bullish
June 02, 2025
Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621. 
Via Stocktwits
Here are the top movers in Monday's session.
June 02, 2025
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Preview: Kymera Therapeutics's Earnings
October 30, 2024
 
Via Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings
October 30, 2024
 
Via Benzinga
Which stocks are experiencing notable movement on Monday?
June 02, 2025
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
June 02, 2025
 
Via Benzinga
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
June 02, 2025
Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026. 
Via Benzinga
These stocks that are showing activity before the opening bell on Monday.
June 02, 2025
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 02, 2025
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
May 30, 2025
 
Via Benzinga
Friday's after hours session: top gainers and losers
May 30, 2025
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts
May 12, 2025
 
Via Benzinga
Earnings Scheduled For May 9, 2025
May 09, 2025
 
Via Benzinga
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
April 27, 2025
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics. 
Via Benzinga
Topics Artificial Intelligence
Why Kymera Therapeutics Stock Crushed it This Week
April 25, 2025
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap